Diagnostic ultrasound ( PDFDrive )

1110 PART IV Obstetric and Fetal Sonography
33. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down’s syndrome
on the basis of tests performed during the irst and second trimesters. N
Engl J Med. 1999;341(7):461-467.
34. Palomaki GE, Steinort K, Knight GJ, Haddow JE. Comparing three screening
strategies for combining irst- and second-trimester Down syndrome markers.
Obstet Gynecol. 2006;107(2 Pt 1):367-375.
35. Cuckle HS, Malone FD, Wright D, et al. Contingent screening for Down
syndrome—results from the FaSTER trial. Prenat Diagn. 2008;28(2):
89-94.
36. Ball RH, Caughey AB, Malone FD, et al. First- and second-trimester evaluation
of risk for Down syndrome. Obstet Gynecol. 2007;110(1):10-17.
37. Platt LD, Greene N, Johnson A, et al. Sequential pathways of testing ater
irst-trimester screening for trisomy 21. Obstet Gynecol. 2004;104(4):
661-666.
38. Haddow JE, Palomaki GE, Knight GJ, et al. Screening of maternal serum
for fetal Down’s syndrome in the irst trimester. N Engl J Med.
1998;338(14):955-961.
39. Snijders RJ, hom EA, Zachary JM, et al. First-trimester trisomy
screening: nuchal translucency measurement training and quality assurance
to correct and unify technique. Ultrasound Obstet Gynecol. 2002;
19(4):353-359.
40. Safety Group of the British Medical Ultrasound Society. Guidelines for the
safe use of diagnostic ultrasound equipment 2009. Available from: https://
www.bmus.org/static/uploads/resources/BMUS-Safety-Guidelines-2009-
revision-FINAL-Nov-2009.pdf. Accessed 18 January 2016.
41. Evans MI, Van Decruyes H, Nicolaides KH. Nuchal translucency measurements
for irst-trimester screening: the ‘price’ of inaccuracy. Fetal Diagn
her. 2007;22(6):401-404.
42. Braithwaite JM, Kadir RA, Pepera TA, et al. Nuchal translucency measurement:
training of potential examiners. Ultrasound Obstet Gynecol.
1996;8(3):192-195.
43. Nicolaides KH. he 11-13+6 weeks scan. London: Fetal Medicine Foundation;
2004.
44. Wax JR, Pinette MG, Cartin A, Blackstone J. he value of repeated evaluation
ater initial failed nuchal translucency measurement. J Ultrasound Med.
2007;26(6):825-828.
45. Breathnach FM, Malone FD, Lambert-Messerlian G, et al. First- and secondtrimester
screening: detection of aneuploidies other than Down syndrome.
Obstet Gynecol. 2007;110(3):651-657.
46. Spencer K, Nicolaides KH. A irst trimester trisomy 13/trisomy 18 risk
algorithm combining fetal nuchal translucency thickness, maternal serum
free beta-hCG and PAPP-A. Prenat Diagn. 2002;22(10):877-879.
47. Baer RJ, Flessel MC, Jellife-Pawlowski LL, et al. Detection rates for aneuploidy
by irst-trimester and sequential screening. Obstet Gynecol. 2015;126(4):
753-759.
48. Santorum M, Wright D, Syngelaki A, et al. Accuracy of irst trimester
combined test in screening for trisomies 21, 18 and 13. Ultrasound Obstet
Gynecol. 2016. Aug 23. [Epub ahead of print.]
49. Malone FD, Ball RH, Nyberg DA, et al. First-trimester septated cystic
hygroma: prevalence, natural history, and pediatric outcome. Obstet Gynecol.
2005;106(2):288-294.
50. Molina FS, Avgidou K, Kagan KO, et al. Cystic hygromas, nuchal edema,
and nuchal translucency at 11-14 weeks of gestation. Obstet Gynecol.
2006;107(3):678-683.
51. Sonek J, Croom C, McKenna D, Neiger R. First-trimester septated cystic
hygroma: prevalence, natural history, and pediatric outcome. Obstet Gynecol.
2006;107(2 Pt 1):424.
52. Cicero S, Dezerega V, Andrade E, et al. Learning curve for sonographic
examination of the fetal nasal bone at 11-14 weeks. Ultrasound Obstet
Gynecol. 2003;22(2):135-137.
53. Cicero S, Curcio P, Papageorghiou A, et al. Absence of nasal bone in fetuses
with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet.
2001;358(9294):1665-1667.
54. Cicero S, Rembouskos G, Vandecruys H, et al. Likelihood ratio for trisomy
21 in fetuses with absent nasal bone at the 11-14-week scan. Ultrasound
Obstet Gynecol. 2004;23(3):218-223.
55. Cicero S, Bindra R, Rembouskos G, et al. Integrated ultrasound and biochemical
screening for trisomy 21 using fetal nuchal translucency, absent fetal
nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Prenat Diagn.
2003;23(4):306-310.
56. Cicero S, Avgidou K, Rembouskos G, et al. Nasal bone in irst-trimester
screening for trisomy 21. Am J Obstet Gynecol. 2006;195(1):109-114.
57. Orlandi F, Rossi C, Orlandi E, et al. First-trimester screening for trisomy-21
using a simpliied method to assess the presence or absence of the fetal
nasal bone. Am J Obstet Gynecol. 2005;192(4):1107-1111.
58. Sepulveda W, Wong AE, Dezerega V. First-trimester ultrasonographic
screening for trisomy 21 using fetal nuchal translucency and nasal bone.
Obstet Gynecol. 2007;109(5):1040-1045.
59. Malone FD, Ball RH, Nyberg DA, et al. First-trimester nasal bone evaluation
for aneuploidy in the general population. Obstet Gynecol. 2004;104(6):
1222-1228.
60. Rosen T, D’Alton ME, Platt LD, Wapner R. First-trimester ultrasound
assessment of the nasal bone to screen for aneuploidy. Obstet Gynecol.
2007;110(2 Pt 1):399-404.
61. Ville Y. What is the role of fetal nasal bone examination in the assessment
of risk for trisomy 21 in clinical practice? Am J Obstet Gynecol.
2006;195(1):1-3.
62. Borrell A, Gonce A, Martinez JM, et al. First-trimester screening for Down
syndrome with ductus venosus Doppler studies in addition to nuchal
translucency and serum markers. Prenat Diagn. 2005;25(10):901-905.
63. Falcon O, Auer M, Gerovassili A, et al. Screening for trisomy 21 by fetal
tricuspid regurgitation, nuchal translucency and maternal serum free
beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol.
2006;27(2):151-155.
64. Abele H, Wagner P, Sonek J, et al. First trimester ultrasound screening for
Down syndrome based on maternal age, fetal nuchal translucency and
diferent combinations of the additional markers nasal bone, tricuspid and
ductus venosus low. Prenat Diagn. 2015;35(12):1182-1186.
65. Hyett J, Perdu M, Sharland G, et al. Using fetal nuchal translucency to
screen for major congenital cardiac defects at 10-14 weeks of gestation:
population based cohort study. BMJ. 1999;318(7176):81-85.
66. Makrydimas G, Sotiriadis A, Ioannidis JP. Screening performance of irsttrimester
nuchal translucency for major cardiac defects: a meta-analysis.
Am J Obstet Gynecol. 2003;189(5):1330-1335.
67. Simpson LL, Malone FD, Bianchi DW, et al. Nuchal translucency and the
risk of congenital heart disease. Obstet Gynecol. 2007;109(2 Pt 1):
376-383.
68. Jellife-Pawlowski LL, Norton ME, Shaw GM, et al. Risk of critical congenital
heart defects by nuchal translucency norms. Am J Obstet Gynecol.
2015;212(4):518 e1-518 e10.
69. Timmerman E, Pajkrt E, Maas SM, Bilardo CM. Enlarged nuchal translucency
in chromosomally normal fetuses: strong association with orofacial clets.
Ultrasound Obstet Gynecol. 2010;36(4):427-432.
70. Salomon LJ, Alirevic Z, Bilardo CM, et al. ISUOG practice guidelines:
performance of irst-trimester fetal ultrasound scan. Ultrasound Obstet
Gynecol. 2013;41(1):102-113.
71. Bromley B, Shipp TD, Lyons J, et al. Detection of fetal structural anomalies
in a basic irst-trimester screening program for aneuploidy. J Ultrasound
Med. 2014;33(10):1737-1745.
72. Wagner P, Sonek J, Hoopmann M, et al. First-trimester screening for trisomy
18, 13, triploidy and Turner syndrome by a detailed early anomaly scan.
Ultrasound Obstet Gynecol. 2016;48(4):446-451.
73. Michailidis GD, Economides DL. Nuchal translucency measurement and
pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet
Gynecol. 2001;17(2):102-105.
74. Westin M, Saltvedt S, Almstrom H, et al. By how much does increased
nuchal translucency increase the risk of adverse pregnancy outcome in
chromosomally normal fetuses? A study of 16,260 fetuses derived from an
unselected pregnant population. Ultrasound Obstet Gynecol. 2007;29(2):
150-158.
75. Souka AP, Krampl E, Bakalis S, et al. Outcome of pregnancy in chromosomally
normal fetuses with increased nuchal translucency in the irst trimester.
Ultrasound Obstet Gynecol. 2001;18(1):9-17.
76. Bilardo CM, Muller MA, Pajkrt E, et al. Increased nuchal translucency
thickness and normal karyotype: time for parental reassurance. Ultrasound
Obstet Gynecol. 2007;30(1):11-18.